secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2023-10-25T23:59:59+00:00
Accession:  0000950170-23-055005
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics reports positive preclinical safety data for RaniPill capsule in 60-day GLP study
--------------------------------------------------------------------------------

- 60-day repeat administration in healthy animals showed no treatment-related adverse events; all animals remained healthy.
- Study evaluated RT-100 (RaniPill with mannitol) vs. mock capsule; supports safety for clinical trials.
- Data enable launch of longer-term trials including Phase II study of RT-102 for osteoporosis planned for 2023.
- RaniPill platform is drug-agnostic, aiming to replace injections for biologics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023055005/0000950170-23-055005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023055005/rani-20231025.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-055005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer